Abstract:Neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are increasing in prevalence but lack targeted therapeutics. Although the pathological mechanisms behind these diseases remain unclear, both ALS and FTD are characterized pathologically by aberrant protein aggregation and inclusion formation within neurons, which correlates with neurodegeneration. Notably, aggregation of several key proteins, including TAR DNA binding protein of 43 kDa (TDP-43), superoxide dismutase 1 (SOD1), and tau, have been implicated in these diseases. Proteomics methods are being increasingly applied to better understand disease-related mechanisms and to identify biomarkers of disease, using model systems as well as human samples. Proteomics-based approaches offer unbiased, high-throughput, and quantitative results with numerous applications for investigating proteins of interest. Here, we review recent advances in the understanding of ALS and FTD pathophysiology obtained using proteomics approaches, and we assess technical and experimental limitations. We compare findings from various mass spectrometry (MS) approaches including quantitative proteomics methods such as stable isotope labeling by amino acids in cell culture (SILAC) and tandem mass tagging (TMT) to approaches such as label-free quantitation (LFQ) and sequential windowed acquisition of all theoretical fragment ion mass spectra (SWATH-MS) in studies of ALS and FTD. Similarly, we describe disease-related protein-protein interaction (PPI) studies using approaches including immunoprecipitation mass spectrometry (IP-MS) and proximity-dependent biotin identification (BioID) and discuss future application of new techniques including proximity-dependent ascorbic acid peroxidase labeling (APEX), and biotinylation by antibody recognition (BAR). Furthermore, we explore the use of MS to detect post-translational modifications (PTMs), such as ubiquitination and phosphorylation, of disease-relevant proteins in ALS and FTD. We also discuss upstream technologies that enable enrichment of proteins of interest, highlighting the contributions of new techniques to isolate disease-relevant protein inclusions including flow cytometric analysis of inclusions and trafficking (FloIT). These recently developed approaches, as well as related advances yet to be applied to studies of these neurodegenerative diseases, offer numerous opportunities for discovery of potential therapeutic targets and biomarkers for ALS and FTD.

Molecular pathology markers of FTD and ALS in blood extracellular vesicles

EVolution in ALS diagnosis: molecular markers in extracellular vesicles

Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders.

Plasma extracellular vesicle tau and TDP-43 as diagnostic biomarkers in FTD and ALS

Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis

Extracellular vesicles and amyotrophic lateral sclerosis: from misfolded protein vehicles to promising clinical biomarkers

Proteomics Approaches for Biomarker and Drug Target Discovery in ALS and FTD

Blood diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis

A fluid biomarker reveals loss of TDP-43 splicing repression in presymptomatic ALS–FTD

Blood-based biomarkers of inflammation in amyotrophic lateral sclerosis

Advance in Research on Biomarkers for Amyotrophic Lateral Sclerosis

Emerging perspectives of synaptic biomarkers in ALS and FTD

Plasma Extracellular Vesicle: a Novel Biomarker for Neurodegenerative Disease Diagnosis

A ferroptosis-based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis

A Panel of miRNA Biomarkers Common to Serum and Brain-Derived Extracellular Vesicles Identified in Mouse Model of Amyotrophic Lateral Sclerosis

Blood extracellular vesicles carrying synaptic function‐ and brain‐related proteins as potential biomarkers for Alzheimer's disease

Unveiling therapeutic biomarkers and druggable targets in ALS: An integrative microarray analysis, molecular docking, and structural dynamic studies

Amyotrophic Lateral Sclerosis: Molecular Mechanisms, Biomarkers, and Therapeutic Strategies

Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis

Extracellular vesicles in Alzheimer’s disease: from pathology to therapeutic approaches

Biomarker Organization in Circulating Extracellular Vesicles: New Applications in Detecting Neurodegenerative Diseases